Pharmaceutical Product Registration: Key Considerations for a Successful Submission of NCEs, Biologics & Biosimilars in Malaysia

Introduction

Pharmaceutical product registration in Malaysia is overseen by the National Pharmaceutical Regulatory Agency (NPRA), under the Ministry of Health (MOH). The agency plays a critical role in regulating pharmaceutical products, ensuring their safety, quality, and efficacy.

For pharmaceutical companies aiming to register New Chemical Entities (NCEs), biologics, and biosimilars in Malaysia, understanding the Regulatory landscape and preparing a tailored registration dossier based on product category, as per ACTD requirement, is crucial for a smooth and timely approval process.

Pharmaceutical Product Registration Pathways in Malaysia 

New Chemical Entities (NCEs) 

New Chemical Entity (NCE) and biologics registration in Malaysia requires full evaluation by the Drug Evaluation Committee (DEC). Depending on product urgency and public health value, the NPRA offers both Standard Review (SRP) and Priority Review (PRP) pathways. Priority Review can significantly shorten timelines if criteria are met.

Biologics 

Biologics, due to their complex structure, demand extensive data on manufacturing processes, quality controls, and clinical evidence. Malaysia aligns with ICH guidelines and evaluates biologics based on a thorough risk-benefit analysis and data consistency.

Biosimilars 

For biosimilars, NPRA drug registration requires comprehensive comparability studies, including physicochemical, non-clinical, and clinical evaluations. Demonstrating similarity to the reference biologic is essential—especially regarding immunogenicity and safety.

Submission Requirements 

• Dossier Format: Submissions must follow the ASEAN Common Technical Dossier (ACTD) or ICH CTD format but must align with ACTD specifically for Malaysia.
• Submission Platform: Applications are processed through the NPRA’s online portal, Quest3+.
• Classification & Screening: Determining the product category (pharmaceutical, biologic, biosimilar) is mandatory before submission. A pre-submission meeting is highly encouraged.
• Local Product Registration Holder (PRH): Foreign companies must appoint a local agent as their PRH to interact with NPRA.

Key Considerations for a Successful Submission 

1. Robust Documentation: Ensure accuracy and consistency across all modules. Inconsistencies are one of the major causes of delay in pharmaceutical product registration.
2. Clinical Data Requirements: NCEs and biosimilars may require country-specific or regionally acceptable clinical trial data. Bridging studies might be necessary.
3. GMP Compliance: Manufacturing sites must comply with GMP standards. Certification from a PIC/S Regulatory Participating Authority is required.
4. CPP and Labeling: A valid Certificate of Pharmaceutical Product (CPP) must be submitted along with locally compliant labeling.
5. Risk Management Plan (RMP): Especially important for biologics, a comprehensive RMP enhances safety profiling and increases reviewer confidence.

Common Pitfalls to Avoid 

• Submitting incomplete or inconsistent documents
• Delayed responses to NPRA queries or screening observations
• Incorrect product classification or skipping the pre-submission consultation

Estimated Timelines 

• NCEs (Standard Review): ~245 working days
• NCEs (Priority Review): ~120 working days
• Biologics: ~245 working days (depending on data quality)
• Biosimilars: ~245 working days

Timelines vary based on submission quality and responsiveness to NPRA feedback.

Summary Table

Conclusion 

A strategic and well-prepared approach to pharmaceutical product registration in Malaysia is essential, especially with increasing Regulatory scrutiny and the complexity of modern pharmaceutical innovations.

Collaborating with Regulatory experts like Freyr ensures that your pharmaceutical product registration dossier meets all compliance standards and improves the chances of faster market entry in Malaysia.